A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2022.2057295
Abstract: ABSTRACT Introduction The efficacy of selinexor, the first commercially available exportin inhibitor, has been evaluated in patients with diffuse large B-cell lymphoma (DLBCL) who have received at least 2 lines of therapy. Its role in… read more here.
Keywords: cell lymphoma; large cell; diffuse large; selinexor treatment ... See more keywords